Summary
Pharmacovigilance Agreements (PVAs) are agreements between two companies based on their Commercial Agreements that require an exchange of safety information between the two companies. PVAs are not stand alone agreements but dependent on the relationships established between two companies regarding at least one medicinal and/or developmental product. The existence of strong PVAs is necessary to support the safety of the product and patient safety globally. PVAs may also be referred to as Safety Data Exchange Agreements by some pharmaceutical companies.
Register to download
Patient Safety and Pharmacovigilance Agreements
You may also be interested in:
Newsletter
Pharmacovigilance Nugget #3 The Challenges of Effective PSMF Maintenance - December 2018
The Pharmacovigilance System Master File (PSMF) is a legal requirement in the European Union (EU). A PSMF shall describe the pharmacovigilance (PV)…
Webcast
Practical Implementation of Signal Detection in Iterative Benefit Risk Evaluation
This webcast with PRA Health Sciences' Jacinta Aniagolu-Johnson (Senior Director, Safety and Risk Management) explores how a well defined signal…
Newsletter
PV Nugget #6 Literature Surveillance
Literature is regarded as a significant source of information in the monitoring of a medicinal product, its safety profile, and benefit-risk balance.…